Truist Financial Reiterates Buy Rating for ICON Public (NASDAQ:ICLR)

Truist Financial restated their buy rating on shares of ICON Public (NASDAQ:ICLR) in a research report sent to investors on Wednesday, Benzinga reports. Truist Financial currently has a $383.00 target price on the medical research company’s stock.

ICLR has been the subject of several other reports. The Goldman Sachs Group started coverage on ICON Public in a research note on Thursday, June 6th. They set a buy rating and a $370.00 price objective for the company. William Blair reissued an outperform rating on shares of ICON Public in a report on Friday, May 31st. TD Cowen upped their price objective on shares of ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a research note on Friday, May 31st. Robert W. Baird lifted their target price on shares of ICON Public from $367.00 to $376.00 and gave the company an outperform rating in a research note on Monday, July 8th. Finally, Barclays decreased their price target on ICON Public from $355.00 to $350.00 and set an overweight rating on the stock in a research report on Friday, July 26th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of Buy and an average price target of $351.67.

ICON Public Trading Up 0.1 %

Shares of ICLR stock opened at $300.00 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The firm has a fifty day moving average of $319.98 and a 200-day moving average of $319.09. ICON Public has a 52-week low of $221.20 and a 52-week high of $347.72. The stock has a market cap of $24.75 billion, a price-to-earnings ratio of 36.50, a P/E/G ratio of 1.29 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the company earned $2.96 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, equities research analysts forecast that ICON Public will post 14.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Several hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in ICON Public by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after purchasing an additional 32 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of ICON Public by 17.4% during the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after buying an additional 42 shares during the last quarter. Motco raised its stake in shares of ICON Public by 1.5% during the first quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after buying an additional 59 shares during the last quarter. First National Bank of Hutchinson lifted its holdings in ICON Public by 5.7% in the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after buying an additional 61 shares during the period. Finally, Riverview Trust Co bought a new position in ICON Public in the first quarter valued at approximately $31,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.